Business
Pacira BioSciences Reports Preliminary Net Product Sales of $59.1 Million for August 2022
-- EXPAREL average daily sales for August 2022 were 108 percent of August 2021 – -- More than 11 million patients have received EXPAREL since launch -- TAMPA,
About this update from Pacira Biosciences, Inc.
[{"type":"text","content":"-- EXPAREL average daily sales for August 2022 were 108 percent of August 2021 – -- More than 11 million patients have received EXPAREL since launch -- TAMPA, Fla., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported preliminary unaudited net product sales of $59.1 million for the month of August 2022. The company’s net product sales include EXPAREL® (bupivacaine liposome injectable suspension), ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), and the iovera° system. The company began recognizing sales of ZILRETTA in November 2021 after completing its acquisition of Flexion Therapeutics, Inc. “August sales were highlighted by year-over-year growth trends improving in the second half of the month and EXPAREL surpassing the 11 million patient mark,” said Dave Stack, chairman and chief executive officer of Pacira BioSciences. “In addition to EXPAREL expansion across all target market segments, we continue to expect improving sales trends through the year for ZILRETTA and iovera° as we broaden education and awareness around these complementary and standalone non-opioid solutions for managing osteoarthritis pain.” August 2022 Preliminary Net Product Sales Highlights EXPAREL net product sales were $46.7 million, compared with $41.4 million for August 2021. The company also reports average daily growth rates for EXPAREL to account for differences in the number of selling days per reporting period. EXPAREL average daily sales for the month of August 2022 were 108 percent of August 2021. The number of EXPAREL selling days were 23 in August 2022 and 22 in August 2021.ZILRETTA net product sales were $9.7 million for August 2022. ZILRETTA sales in August 2021 occurred prior to the completion of the company’s acquisition of Flexion in November 2021.iovera° net product sales were $1.5 million for August 2022, compared with $0.9 million for August 2021.Sales of bupivacaine liposome injectable suspension to a third-party licensee for use in veterinary practice were $1.2 million in August 2022. Since early 2020, the company’s revenues have been impacted by COVID-19 and pandemic-related challenges that included the significant postponement or suspension in the scheduling of electi...